Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06162676
Other study ID # STUDY00009385
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 2023
Est. completion date June 2025

Study information

Verified date December 2023
Source Michigan State University
Contact ANGELA CHEN, PhD
Phone 3135361937
Email HPVgame@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine the feasibility and acceptability of an innovative game-based intervention designed for families of youth aged 11-14 to promote HPV vaccination; will explore changes in key outcomes and related measures; and will identify factors contributing to or impeding effective implementation in health clinic settings. The intervention and its approach have the potential to reduce health disparities in HPV-associated cancers in youth via low-cost technology and timely intervention.


Description:

Guided by Social Cognitive Theory, we propose to 1. examine the feasibility and acceptability of a new HPV preventive intervention, the HPV Detective video game, designed for youth and their parents; 2. explore pre-post, intervention-related change in vaccine intent and uptake as well as change in theoretically posited intervention mediators; and 3. assess the potential for broader intervention implementation. Using a sequential mixed-methods, 2-group (intervention vs usual care), longitudinal design, 64 parent-youth dyads (32/per study condition) will be recruited. Parent-youth dyads in the intervention will play HPV Detective (tablet format) at the clinic prior to the healthcare provider visits. The control dyads will receive standard clinic treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 131
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 11 Years to 14 Years
Eligibility Inclusion Criteria: - Youth: (1) 11-14 years old; (2) have not received the 1st dose of HPV vaccine; (3) speak and read English - Parent: (1) are the parent/legal guardian of the participating child; (2) = 18 years old; (3) speak English or Spanish; (4) own a smartphone; (5) agree to participate in the research activities at study sites; (6) agree to receive text messages. - Healthcare providers: (1) = 20 years old; (2) speak English or Spanish); (3) work at study sites Exclusion Criteria: - Individuals are unable to comprehend the consent or assent forms due to cognitive issues

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
HPV game
A brief health game for parent-child dyads to promote child's HPV vaccination

Locations

Country Name City State
United States Michigan State University East Lansing Michigan

Sponsors (2)

Lead Sponsor Collaborator
Michigan State University Arizona State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of eligible individuals agreeing to participate Assessed by the % of eligible individuals agreeing to participate 2 years
Primary Percentage of eligible individuals who complete the intervention (intervention arm only) and assessments (all participants) Assessed by the % of eligible individuals who complete the intervention and assessments 2 years
Primary Ease of use (intervention arm only) (1) device-recorded time to complete interactive modules and the full game; (2) self reported easy of use 2 years
Primary Parent and child acceptability of the intervention (intervention arm only) Assessed by a 12-item Likert scale. 2 years
Primary Intention to vaccinate the child against HPV Assessed by a Likert scale question: how likely will you (parent) vaccinate your child against HPV? Responses: (1) Very unlikely to (5) Very likely 2 years
Primary Child vaccination status (1st & 2nd doses). Assessed by one binary (yes/no) question regarding whether or not the child has received the 1st & 2nd dose of HPV vaccine. 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04098744 - Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) Phase 2
Completed NCT04083196 - A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years Phase 1
Completed NCT04191967 - Thermocoagulation for Treatment of Precancerous Cervical Lesions N/A
Withdrawn NCT04430907 - HPV Vaccine in Postpartum Women
Recruiting NCT02593968 - Yallaferon in Chinese Population Phase 2
Completed NCT04711265 - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Completed NCT02263378 - A New Supplement for the Immune Response to HPV Infection N/A
Completed NCT05234112 - Prevention and Screening Towards Elimination of Cervical Cancer N/A
Completed NCT04590521 - HPV Vaccine Immunity in High-risk Women Phase 4
Recruiting NCT05829629 - Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women Phase 1
Recruiting NCT06052033 - Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection N/A
Recruiting NCT05051852 - HPV Viral Load in Predicting the Prognosis of LSIL
Completed NCT04155294 - Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV
Completed NCT06177236 - Clinic or Self-Sampling for Cervical Cancer Screening N/A
Active, not recruiting NCT04794660 - The Study for the "Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa" Phase 3
Recruiting NCT05509413 - DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections N/A
Recruiting NCT06137950 - Interferon Alpha Therapy for Cervical CINI and HPV Infection Phase 1
Recruiting NCT04171505 - Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
Active, not recruiting NCT05524025 - The SPOT-HPV Study
Recruiting NCT04998318 - 1:1 Comparison of the Pocket Colposcope in Kenya N/A